Equity · Healthcare
SRPT
NASDAQSarepta Therapeutics (SRPT)
The line runs 18.12 USD on 24 August through 13.34 USD on 20 November, on a scale from 10 to 25. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.4B USD
- Revenue, year to Dec 2025
- 1.9B USD
- EPS, diluted, year to Dec 2025
- −7.13 USD
- 52-week range
- 13.34 USD – 24 USD
- Avg volume
- 122.1K
- Mentions, 30 days
- 1
as of Nov 20, 2026
Have Sarepta Therapeutics (SRPT) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, no Sarepta Therapeutics insider bought or sold shares on the open market; all 4 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 22 Nov 2026, newest Form 4 filing 4 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 04 Sep 2026 | Wong Ryan Ho-YanChief Financial Officer | Tax withheld | 13,272 | 295K USD |
| 04 Sep 2026 | Estepan Ian MichaelChief Operating Officer | Tax withheld | 24,799 | 551K USD |
| 04 Sep 2026 | Rothfuss CristinEVP, General Counsel | Tax withheld | 22,025 | 489K USD |
| 04 Sep 2026 | Rodino-Klapac LouisePresident, R&D and Tech Ops | Tax withheld | 21,423 | 476K USD |
Which funds hold Sarepta Therapeutics (SRPT)?
8 of the 45 institutional funds we track reported a Sarepta Therapeutics position for the quarter ended 30 Sep 2026 — a combined 209.7M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Two Sigma Investments | Held (±25%) | 4,475,965 | 81.6M USD | −2.7% |
| Balyasny Asset Management | Added | 2,452,560 | 44.7M USD | +1,510.6% |
| Marshall Wace | Held (±25%) | 2,015,950 | 36.7M USD | −8.6% |
| Point72 Asset Management | Added | 805,759 | 14.7M USD | +57.7% |
| Bridgewater Associates | Added | 595,648 | 10.9M USD | +291.7% |
| Renaissance Technologies | Trimmed | 454,278 | 8.3M USD | −59.5% |
| AQR Capital Management | Trimmed | 395,674 | 7.2M USD | −90.9% |
| Millennium Management | Trimmed | 311,106 | 5.7M USD | −73.9% |
| Man Group | Exited |
Have members of Congress traded Sarepta Therapeutics (SRPT)?
The most recent congressional trade disclosed in Sarepta Therapeutics is a sale by Gilbert Ray Cisneros, Jr. (house, CA), dated 14 Apr 2025.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 14 Apr 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Sale | 1K USD–15K USD | 22 days |
| 14 Jul 2023 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 38 days |
| 13 Jun 2023 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 28 days |
| 06 Mar 2023 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 45 days |
| 06 Mar 2023 | Daniel S. Goldmanhouse · Democrat–NY | Purchase | 15K USD–50K USD | 42 days |
| 31 Jan 2023 | Daniel S. Goldmanhouse · Democrat–NY | Sale | 1K USD–15K USD | 24 days |
| 14 Sep 2020 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 30 days |
| 10 Oct 2019 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 36 days |
What has been filed or recorded for Sarepta Therapeutics (SRPT)?
The filings we hold for Sarepta Therapeutics, newest first: 3 fails-to-deliver days, 4 quarterly earnings reports, 3 annual reports and 5 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,783 shares | 54K USD notional · 0.003% of shares out |
| 28 Oct 2026 | Fails to deliver | Shares failed to deliver | 11,085 shares | 209K USD notional · 0.010% of shares out |
| 15 Oct 2026 | Fails to deliver | Shares failed to deliver | 6,934 shares | 117K USD notional · 0.006% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.27 USD | Revenue $381M |
| 30 Sep 2026 | Financials | Total assets | 3.2B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 1.5B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.05 USD | Revenue $401M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 2.88 USD | Revenue $731M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −3.93 USD | Revenue $443M |
| 31 Dec 2025 | Financials | Revenue | 1.9B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −713.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −7.13 USD | fiscal year |
| 30 Sep 2025 | Annual report | FY 2025 reported | EPS −0.50 USD | Revenue $399M |
| 30 Jun 2025 | Annual report | FY 2025 reported | EPS 1.89 USD | Revenue $611M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −4.60 USD | Revenue $745M |
What is Reddit saying about Sarepta Therapeutics (SRPT)?
Reddit mentioned SRPT 1 times in the 30 days to 21 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 0% read bullish, 100% bearish and 0% neither. Reddit data updated 21 November 2026.
30-day window, Method
How do Reddit mentions of Sarepta Therapeutics (SRPT) compare with its price?
Share ↗
Which subreddits are talking about Sarepta Therapeutics (SRPT)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 100% | 1 | −0.36 |
What do people ask about Sarepta Therapeutics (SRPT)?
What did Sarepta Therapeutics shares close at?13.34
Sarepta Therapeutics closed at 13.34 USD on 20 Nov 2026, down 5.83% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Sarepta Therapeutics’ market cap?1.4B
Sarepta Therapeutics is worth 1.4B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Sarepta Therapeutics’ revenue?1.9B
Sarepta Therapeutics reported revenue of 1.9B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Sarepta Therapeutics insiders bought or sold shares recently?4 filings
In the 90 days to 22 Nov 2026, no Sarepta Therapeutics insider bought or sold shares on the open market; all 4 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own Sarepta Therapeutics?8 of 45
8 of the 45 funds we track reported a Sarepta Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, Balyasny Asset Management and Marshall Wace. See Funds
Have members of Congress traded Sarepta Therapeutics?10 trades
Yes. 10 trades in Sarepta Therapeutics appear in the congressional disclosures we hold; the latest is a sale by Gilbert Ray Cisneros, Jr. (House, CA) dated 14 Apr 2025, filed 6 May 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Sarepta Therapeutics last report earnings?−0.27
Sarepta Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.27 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Sarepta Therapeutics?0 mentions
Sarepta Therapeutics was mentioned 0 times in the last 7 days across the finance subreddits we track, and 1 times over the trailing 30 days. Of the 1 mentions scored for sentiment, 0% read bullish and 100% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Josh Gottheimer: Kristie Boyd; U.S. House Office of Photography, Public domain; Daniel S. Goldman: US House, Public domain; Gilbert Ray Cisneros, Jr.: United States Department of Defense, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- Wikipediatext of the lead paragraph, licensed CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/) — https://en.wikipedia.org/wiki/Sarepta_Therapeutics